{
    "organizations": [],
    "uuid": "899d3de3f4af7dbd2dfd8452a453f8e9e85a1569",
    "author": "",
    "url": "https://www.reuters.com/article/brief-rxi-pharmaceuticals-says-49-mln-re/brief-rxi-pharmaceuticals-says-4-9-mln-registered-direct-offering-priced-at-the-market-idUSASC09VB0",
    "ord_in_thread": 0,
    "title": "BRIEF-Rxi Pharmaceuticals Says $4.9 Mln Registered Direct Offering Priced At-The Market",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 9, 2018 / 6:10 PM / in 8 minutes BRIEF-Rxi Pharmaceuticals Says $4.9 Mln Registered Direct Offering Priced At-The Market Reuters Staff \nApril 9 (Reuters) - Rxi Pharmaceuticals Corp: \n* RXI PHARMACEUTICALS ANNOUNCES $4.9 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET \n* ENTERED AGREEMENTS FOR PURCHASE OF 1.5 MLN SHARES AT $3.24375/SHARE IN REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET \n* TO USE PROCEEDS FROM OFFERING TO FUND PRECLINICAL & CLINICAL DEVELOPMENT, OTHER RESEARCH & DEVELOPMENT ACTIVITIES, AMONG OTHERS Source text for Eikon: Further company coverage:",
    "published": "2018-04-09T21:09:00.000+03:00",
    "crawled": "2018-04-09T21:26:00.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "minute",
        "pharmaceutical",
        "say",
        "mln",
        "registered",
        "direct",
        "offering",
        "priced",
        "market",
        "reuters",
        "staff",
        "april",
        "reuters",
        "rxi",
        "pharmaceutical",
        "corp",
        "rxi",
        "pharmaceutical",
        "announces",
        "million",
        "registered",
        "direct",
        "offering",
        "priced",
        "entered",
        "agreement",
        "purchase",
        "mln",
        "share",
        "registered",
        "direct",
        "offering",
        "priced",
        "use",
        "proceeds",
        "offering",
        "fund",
        "preclinical",
        "clinical",
        "development",
        "research",
        "development",
        "activity",
        "among",
        "others",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}